FDA Approved: NUPLAZID — Supplemental Application (Acadia Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for NUPLAZID (pimavanserin tartrate) submitted by Acadia Pharmaceuticals, signaling a labeling update for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease Psychosis

Drugs mentioned

• Nuplazid (Pimavanserin)

Snippet

SUPPL AP for NUPLAZID (PIMAVANSERIN TARTRATE)